Psoriasis is a chronic skin disease that manifests itself mainly with skin symptoms (dryness, itching, scaly skin, abnormal ...

The painkiller commonly used to relieve headaches, toothache, back pain and cold symptoms, may speed up reaction times, boost ...

The next big advance in treating diseases like rheumatoid arthritis could be tiny pulses of electricity delivered to the ...

Paradigm Biopharmaceuticals has selected Advanced Clinical as the preferred clinical research organisation for the phase III ...

The emotional and physical toll doctors battle when they fall sick and become patients, facing the same fears and ...

Even without a lot of social media use, disinformation finds older Americans. It’s on their phones, in their texts, in their ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both ...

As millions of Americans experience the benefits of weight loss through the use of GLP-1 medications, some orthopedic experts are still torn on the potential effects the medications will have for ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.